|
|
|
Stelazine advertisement, 1990 American Journal of Psychiatry, Vol. 147, No. 1. Emerging from the Darkness of Schizophrenia Stelazine® brand of trifluoperazine HCl ~ Controls psychotic symptoms ~ "Activates" the withdrawn patient ~ Avoids excessive sedation ~ Reduces the risk of side effects* ~ Encourages adherence with b.i.d. dosing *With 'Stelazine', the risk of anticholinergic effects and hypotension is relatively low. 'Stelazine' shares the increased risk of extrapyramidal symptoms associated with all high-potency neuroleptics; when they occur, these can generally be readily controlled. Adverse reactions: Drowsiness, dizziness, skin reactions, rash, dry mouth, insomnia, amenorrhea, fatigue, muscular weakness, anorexia, lactation, blurred vision. Neuromuscular (extrapyramidal) reactions: motor restlessness, dystonias, pseudo-parkinsonism, tardive dyskinesia, and a variant, tardive dystonia. NOTE: Sudden death in patients taking phenothiazines (apparently due to cardiac arrest or asphyxia due to failure of cough reflex) has been reported. © SK&F Lab Co., 1989 |